Brief: Sutro Biopharma Announces Initiation Of The Registration-Enabling REFRαME-P1 Trial With Luvelta For Pediatric Patients With CBF/GLIS AML
01/11/2024 12:12
Nov 1 (Reuters) - Sutro Biopharma Inc STRO.O :
* SUTRO BIOPHARMA ANNOUNCES INITIATION OF THE
REGISTRATION-ENABLING REFRΑME-P1 TRIAL WITH LUVELTA FOR
PEDIATRIC PATIENTS WITH CBF/GLIS AML
Source text: ID:nGNXbFjtX4
Further company coverage: STRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates